160 related articles for article (PubMed ID: 22824154)
1. Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum-bisphosphonate complexes in the treatment of bone tumors: a mini-review.
Iafisco M; Margiotta N
J Inorg Biochem; 2012 Dec; 117():237-47. PubMed ID: 22824154
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate complexation and calcium doping in silica xerogels as a combined strategy for local and controlled release of active platinum antitumor compounds.
Margiotta N; Ostuni R; Teoli D; Morpurgo M; Realdon N; Palazzo B; Natile G
Dalton Trans; 2007 Aug; (29):3131-9. PubMed ID: 17637988
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
Margiotta N; Ostuni R; Gandin V; Marzano C; Piccinonna S; Natile G
Dalton Trans; 2009 Dec; (48):10904-13. PubMed ID: 20023921
[TBL] [Abstract][Full Text] [Related]
4. Nanocrystalline carbonate-apatites: role of Ca/P ratio on the upload and release of anticancer platinum bisphosphonates.
Iafisco M; Palazzo B; Martra G; Margiotta N; Piccinonna S; Natile G; Gandin V; Marzano C; Roveri N
Nanoscale; 2012 Jan; 4(1):206-17. PubMed ID: 22075933
[TBL] [Abstract][Full Text] [Related]
5. Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor.
Nakatake H; Ekimoto H; Aso M; Ogawa A; Yamaguchi A; Suemune H
Chem Pharm Bull (Tokyo); 2011; 59(6):710-3. PubMed ID: 21628905
[TBL] [Abstract][Full Text] [Related]
6. Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix.
Hochdörffer K; Abu Ajaj K; Schäfer-Obodozie C; Kratz F
J Med Chem; 2012 Sep; 55(17):7502-15. PubMed ID: 22882004
[TBL] [Abstract][Full Text] [Related]
7. A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues.
Margiotta N; Capitelli F; Ostuni R; Natile G
J Inorg Biochem; 2008 Dec; 102(12):2078-86. PubMed ID: 18760482
[TBL] [Abstract][Full Text] [Related]
8. Pamidronate-Conjugated Biodegradable Branched Copolyester Carriers: Synthesis and Characterization.
Oledzka E; Pachowska D; Orłowska K; Kolmas J; Drobniewska A; Figat R; Sobczak M
Molecules; 2017 Jun; 22(7):. PubMed ID: 28672871
[TBL] [Abstract][Full Text] [Related]
9. Advances in platinum chemotherapeutics.
Harper BW; Krause-Heuer AM; Grant MP; Manohar M; Garbutcheon-Singh KB; Aldrich-Wright JR
Chemistry; 2010 Jun; 16(24):7064-77. PubMed ID: 20533453
[TBL] [Abstract][Full Text] [Related]
10. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
11. Controlled Release of Chemotherapeutic Platinum-Bisphosphonate Complexes from Injectable Calcium Phosphate Cements.
Farbod K; Sariibrahimoglu K; Curci A; Hayrapetyan A; Hakvoort JN; van den Beucken JJ; Iafisco M; Margiotta N; Leeuwenburgh SC
Tissue Eng Part A; 2016 May; 22(9-10):788-800. PubMed ID: 27083055
[TBL] [Abstract][Full Text] [Related]
12. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
13. Dinuclear Pt(II)-bisphosphonate complexes: a scaffold for multinuclear or different oxidation state platinum drugs.
Piccinonna S; Margiotta N; Pacifico C; Lopalco A; Denora N; Fedi S; Corsini M; Natile G
Dalton Trans; 2012 Aug; 41(32):9689-99. PubMed ID: 22782180
[TBL] [Abstract][Full Text] [Related]
14. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.
Hirabayashi H; Fujisaki J
Clin Pharmacokinet; 2003; 42(15):1319-30. PubMed ID: 14674786
[TBL] [Abstract][Full Text] [Related]
15. Slow release of anticancer drugs from porous calcium hydroxyapatite ceramic.
Uchida A; Shinto Y; Araki N; Ono K
J Orthop Res; 1992 May; 10(3):440-5. PubMed ID: 1314896
[TBL] [Abstract][Full Text] [Related]
16. Heterobifunctional poly(ethylene glycol) derivatives for the surface modification of gold nanoparticles toward bone mineral targeting.
Zayed GM; Tessmar JK
Macromol Biosci; 2012 Aug; 12(8):1124-36. PubMed ID: 22807219
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyapatite nanocrystals as a smart, pH sensitive, delivery system for kiteplatin.
Lelli M; Roveri N; Marzano C; Hoeschele JD; Curci A; Margiotta N; Gandin V; Natile G
Dalton Trans; 2016 Aug; 45(33):13187-95. PubMed ID: 27397134
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in research applications of nanophase hydroxyapatite.
Fox K; Tran PA; Tran N
Chemphyschem; 2012 Jul; 13(10):2495-506. PubMed ID: 22467406
[TBL] [Abstract][Full Text] [Related]
19. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
Wong DY; Yeo CH; Ang WH
Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
[TBL] [Abstract][Full Text] [Related]
20. Potential photoactivated metallopharmaceuticals: from active molecules to supported drugs.
Crespy D; Landfester K; Schubert US; Schiller A
Chem Commun (Camb); 2010 Sep; 46(36):6651-62. PubMed ID: 20717579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
